ESC 2022 Investor Presentation: Nomination of VERVE-201 ANGPTL3 Product Candidate

An in vivo CRISPR base editing therapy to inactivate ANGPTL3: nomination of a development candidate for VERVE-201

Amit V. Khera MD MSc

Verve Therapeutics

ESC Congress

August 29, 2022

1

Forward looking statements

This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the initiation, and timing, of the Company's planned regulatory submissions, future clinical trial initiation of VERVE-201, its research and development plans and the potential advantages and therapeutic potential of the Company's programs. All statements, other than statements of historical facts, contained in this presentation, including statements regarding the Company's strategy, future operations, future financial position, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-

looking statements contain these identifying words. Any forward-looking statements are based on management's current expectations of future events and are

subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward- looking statements. These risks and uncertainties include, but are not limited to, risks associated with the Company's limited operating history; the timing of and the Company's ability to submit applications for, and obtain and maintain regulatory approvals for, its product candidates; continue to advance its product candidates in

clinical trials; initiate and enroll patients in clinical trials on the timeline expected or at all; correctly estimate the potential patient population and/or market for the Company's product candidates; replicate in clinical trials positive results found in preclinical studies and/or earlier-stage clinical trials of VERVE-101 and VERVE-201; advance the development of its product candidates under the timelines it anticipates in current and future clinical trials; obtain, maintain or protect intellectual property rights related to its product candidates; manage expenses; and raise the substantial additional capital needed to achieve its business objectives. For a

discussion of other risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the "Risk Factors" section, as well as discussions of potential risks, uncertainties and other important factors, in the Company's most recent filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this presentation represent the Company's views as of the date hereof and should not be relied upon as representing the Company's views as of any date subsequent to the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements

at some point in the future, the Company specifically disclaims any obligation to do so.

2

Goal of ANGPTL3 program: turn off gene (permanently) in liver with base editing to lower LDL-C and treat ASCVD

3

Advancing a pipeline of single-coursein vivo gene editing programs to safely and durably lower LDL-C and treat ASCVD

				DEVELOPMENT STATUS
PROGRAM	INDICATIONS	Research/
		IND-Enabling	Phase 1	Phase 2	Phase 3
		Lead optimization

Low-density lipoprotein cholesterol (LDL-C)

VERVE-101

PCSK9

Heterozygous familial hypercholesterolemia

ASCVD not at LDL-C goal on oral therapy

LDL-C & Triglyceride-rich lipoprotein (TRL)

VERVE-201

ANGPTL3

Homozygous familial hypercholesterolemia

ASCVD not at LDL-C goal on oral + PCSK9i

4

Two indications with high unmet need

Homozygous familial	Atherosclerotic CVD
hypercholesterolemia	not at LDL-C goal on oral SOC + PCSK9i

		47%			32%
			NOT AT GOAL				NOT AT GOAL
			AT GOAL				AT GOAL
			In a global registry of HoFH patients,		In the ORION-9,-10, and -11 clinical trials of inclisiran,
			47% did not attain LDL-C goal				32% did not attain LDL-C < 70 mg/dl
			even on 5 lipid-lowering therapies				even on oral (statin) + PCSK9i (inclisiran) therapy
							Slide previously presented at 2022 ACC Scientific Sessions
			Tromp et al. | Lancet | 2022≈				Wright et al. | J Am Coll Card | 2021	5